Form 4: BridgeBio Pharma Officer Granted 14,170 RSUs

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, received a grant of 14,170 restricted stock units under the company's incentive plan.

Summary

• Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc. (BBIO), was granted 14,170 restricted stock units (RSUs) on March 18, 2026.
• The RSUs were granted under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of BridgeBio Pharma's Common Stock.
• The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026, and an additional 1/16th each quarter thereafter until fully vested.
• Vesting is contingent upon Ms. Apuli's continued service with the Issuer or its subsidiaries through each vesting date.
• Following this transaction, Ms. Apuli beneficially owns 136,115 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation and retention practices, which generally align management incentives with long-term company performance. It's a routine transaction with no immediate negative implications beyond minor future dilution.

Positives

• The grant of restricted stock units serves as a retention mechanism for a key executive, aligning management's interests with long-term shareholder value.
• The vesting schedule encourages continued service and performance from the Chief Accounting Officer.

Negatives

• The issuance of new shares upon RSU vesting will result in a minor dilution of existing shareholder equity over time.

Risks

• The vesting of RSUs is subject to the reporting person's continued service, meaning the shares may not be fully realized if employment ceases before full vesting.

Future Outlook

The future outlook indicates a structured vesting schedule for the granted RSUs, with the first tranche vesting on May 16, 2026, and subsequent tranches vesting quarterly thereafter, contingent on continued employment.

Management Comments

• "/s/ Maricel Apuli" (Signature of Reporting Person)

Industry Context

StockSavvy.ai notes that RSU grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industry, designed to attract, retain, and incentivize key talent by linking their long-term financial interests to the company's performance and stock appreciation. This grant to a Chief Accounting Officer is consistent with typical compensation practices for senior financial executives in publicly traded life sciences companies.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a compensation tool is a common practice across the biotechnology and pharmaceutical sectors, similar to companies like Moderna, Pfizer, or Amgen, which frequently utilize equity awards to align executive incentives with shareholder value.
• The vesting schedule, typically over several years and contingent on continued service, is standard for RSU grants in the industry, promoting long-term commitment from executives.
• The grant size of 14,170 RSUs for a Chief Accounting Officer at a company like BridgeBio Pharma appears to be within a reasonable range for a senior executive role, comparable to similar grants observed at mid-to-large cap biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential future dilution upon RSU vesting, but also improved alignment of executive interests with long-term company performance.
• Employees: Reflects ongoing use of equity compensation, which can be a positive signal for employee retention and motivation within the company.

Next Steps

• 1/16th of the granted RSUs will vest on May 16, 2026.
• Subsequent 1/16th portions of the RSUs will vest quarterly thereafter until fully vested, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and does not contain information significant enough to alter an investment thesis. It's a standard practice for executive retention and incentive alignment, which is generally positive but not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should 'hold' and consider this as part of the ongoing operational and governance landscape.

Keywords

BridgeBio Pharma, BBIO, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Maricel Apuli